CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 103,996	$ 123,794
Accounts receivable, net of reserves of $3,831 in 2019 and $4,702 in 2018	268,319	248,855
Inventories	204,893	173,303
Other current assets	126,174	108,220
Total current assets	703,382	654,172
Long-Term Assets:
Property and equipment, net	496,584	437,270
Operating lease right-of-use assets (Notes 2 and 8)	78,977	0
Goodwill	212,171	214,489
Intangible assets, net	35,662	41,825
Other long-term assets	224,705	189,593
Total long-term assets	1,048,099	883,177
TOTAL ASSETS	1,751,481	1,537,349
Current Liabilities:
Accounts payable	75,515	69,534
Accrued liabilities	278,626	260,683
Line of credit	229,500	398,937
Current portion of deferred revenue	42,986	41,290
Total current liabilities	626,627	770,444
Long-Term Liabilities:
Deferred income tax liabilities	33,734	29,267
Long-term debt	696,634	601,348
Long-term deferred revenue, net of current portion	48,345	60,697
Long-term operating lease liabilities (Notes 2 and 8)	66,341	0
Other long-term liabilities	77,078	84,826
Total long-term liabilities	922,132	776,138
Total liabilities	1,548,759	1,546,582
Commitments and Contingencies (Note 16)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 105,594 shares in 2019 and 105,087 shares in 2018; Outstanding: 85,888 shares in 2019 and 86,100 shares in 2018	10,559	10,509
Additional paid-in capital	1,189,554	1,138,216
Deferred stock units: Outstanding: 143 units in 2019 and 162 units in 2018	4,416	4,524
Retained earnings	1,505,152	1,167,928
Accumulated other comprehensive loss	(45,565)	(41,791)
Treasury stock, at cost: 19,707 shares in 2019 and 18,988 shares in 2018	(2,461,698)	(2,288,899)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	202,418	(9,513)
Noncontrolling interest	304	280
Total stockholders’ equity (deficit)	202,722	(9,233)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,751,481	$ 1,537,349